Over the past decades, improvements in computers and networking, radiation therapy treatment planning software, and medical imaging modalities (CT, MRI, US, and PET) have been incorporated into radiation therapy practice. Often, devices are used to track the motion and position of the equipment that is used to deliver a treatment. The amount of radiation that is delivered to a patient during a treatment is also monitored in order to deliver the correct dose (e.g., amount of radiation) to the appropriate target treatment area. Typically, equipment and patient position information is gathered via mechanical sensors that are hard-wired to control computers.
In one embodiment, the invention provides a local positioning system (“LPS”), to control, verify, synchronize, and/or QA radiation therapy treatment systems or imaging device systems. This can be done in real-time or as a post-process. An aspect of the invention includes an interface between the LPS and other positioning systems, and the use of this information for machine control, synchronization, and/or patient procedures, such as imaging or therapy. In another aspect, the LPS can communicate with other patient monitoring devices to acquire information to use for machine control, synchronization, and/or patient procedures.
Another embodiment of the invention includes a method for tracking different hardware components in the context of patient imaging or treatment. These components can include gantries, couches, collimators (both the base and/or individual leaves) or other components for which feedback is desired. Sensors for this system could also be affixed to patients.
One method of positioning feedback utilizes mechanical sensors that are typically hard-wired to control computers. Other methods of feedback focus on patient monitoring, and these include implantable RF devices that can be inserted into the patient. Some of these devices use MOSFET technology to provide feedback on dose received, while others provide readout of location.
In another embodiment, the invention provides a radiation imaging and/or therapy-treatment system. The system comprises a radiation source, a movable apparatus, a controller configured to control, including moving, the movable apparatus, and a local positioning system. The local position system includes a position verification device directly coupled to the movable apparatus and a system monitoring module in communication with the position verification device. The local positioning system is configured to determine position data for the position verification device.
In another embodiment, the invention provides a method of evaluating dose delivered by a radiation therapy system using a marker that indicates motion. The marker is associated with the patient. The method comprises the acts of delivering radiation to the patient, monitoring motion of the marker during the delivering radiation, and evaluating a dose delivered to the patient based at least in part on the motion of the marker.
In another embodiment, the invention provides a method of evaluating dose delivered by a radiation therapy system using a marker associated with the patient. The method comprises the acts of delivering radiation to the patient, obtaining information relating to the delivery of radiation, estimating dose to the marker based at least in part on the information, acquiring dose received by the marker, and comparing the received dose with the estimated dose.
In another embodiment, the invention proves a method of evaluating dose delivered by a radiation therapy system using a marker that indicates motion. The marker is associated with the patient. The method comprises the acts of delivering radiation to the patient, monitoring motion of the marker during the delivering radiation, estimating a dose delivered to the patient based at least in part on the motion of the marker, acquiring dose received by the marker, and comparing the received dose with the estimated dose.
Other aspects of the invention will become apparent by consideration of the detailed description and accompanying drawings.
Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. Unless specified or limited otherwise, the terms “mounted,” “connected,” “supported,” and “coupled” and variations thereof are used broadly and encompass both direct and indirect mountings, connections, supports, and couplings. Further, “connected” and “coupled” are not restricted to physical or mechanical connections or couplings.
Although directional references, such as upper, lower, downward, upward, rearward, bottom, front, rear, etc., may be made herein in describing the drawings, these references are made relative to the drawings (as normally viewed) for convenience. These directions are not intended to be taken literally or limit the invention in any form. In addition, terms such as “first”, “second”, and “third” are used herein for purposes of description and are not intended to indicate or imply relative importance or significance.
In addition, it should be understood that embodiments of the invention include hardware, software, and electronic components or modules that, for purposes of discussion, may be illustrated and described as if the majority of the components were implemented solely in hardware. However, one of ordinary skill in the art, and based on a reading of this detailed description, would recognize that, in at least one embodiment, the electronic based aspects of the invention may be implemented in software. As such, it should be noted that a plurality of hardware and software based devices, as well as a plurality of different structural components may be utilized to implement the invention. Furthermore, and as described in subsequent paragraphs, the specific mechanical configurations illustrated in the drawings are intended to exemplify embodiments of the invention and that other alternative mechanical configurations are possible.
The gantry 18 can support a radiation module, having a radiation source 22 and a linear accelerator 26 operable to generate a beam 30 of photon radiation. The radiation module can also include a modulation device 34 operable to modify or modulate the radiation beam 30. The modulation device 34 provides the modulation of the radiation beam 30 and directs the radiation beam 30 toward the patient 14. Specifically, the radiation beam 30 is directed toward a portion of the patient. Broadly speaking, the portion may include the entire body, but is generally smaller than the entire body and can be defined by a two-dimensional area and/or a three-dimensional volume. A portion desired to receive the radiation, which may be referred to as a target or target region (shown as 46), is an example of a region of interest. Another type of region of interest is a region at risk. If a portion includes a region at risk, the radiation beam is preferably diverted from the region at risk. The patient 14 may have more than one target region 46 that needs to receive radiation therapy. Such modulation is sometimes referred to as intensity modulated radiation therapy (“IMRT”).
Other frameworks capable of positioning the radiation module at various rotational and/or axial positions relative to the patient 14 may also be employed. In addition, the radiation source 22 may travel in path that does not follow the shape of the gantry 18. For example, the radiation source 24 may travel in a non-circular path even though the illustrated gantry 18 is generally circular-shaped.
In one construction, and illustrated in
The radiation therapy treatment system 10 (
The radiation therapy treatment system 10 can also include a patient support, such as a couch 62 (illustrated in
The radiation therapy treatment system 10, as described above, includes many components and mechanisms (e.g., the couch 62, the MLC 38, the gantry 18, etc.) that can move from one position to another in order to deliver a desired dose (e.g., a predetermined amount of radiation) to the patient 14. For example, the leaves 42 of the MLC 38 can move in order to modulate the intensity of radiation that is being delivered to the patient 14. Additionally, the couch 62 can move in order to properly position the target 46. The motion of each of the components of the treatment system 10, therefore, can be precisely controlled to deliver the proper dose to the patient 14. The motions (as well as operations) of the components and mechanisms of the treatment system 10 can be controlled with a plurality of computers and/or controllers (e.g., the gantry controller 20, the couch controller 70, the MLC controller 54, etc.). Other controllers, such as a dose controller 75 (shown in
Alternatively, a single system computer (not shown) can be used to control the entire treatment system 10, which incorporates the processes and operations of all of the separate controllers and/or computers.
Before proceeding further, it should be understood that the plurality of position verification devices 125 may also be referred to herein as the plurality of motion verification devices 125. As discussed herein, the position verification devices 125 can be used to acquire a velocity (or speed), an acceleration, or a time series for the devices 125. The position information, velocity information, acceleration information, and time series information can be collectively referred to herein as motion information, hence the possible use of the term “motion verification device” in alternative to “position verification device.” Also as discussed herein, the position verification devices 125 (or motion verification devices 125) can be used to monitor radiation to the position verification devices 125.
As shown in
Referring still to
The position verification device 125 can also supply position data that is relative to other components, for example, the couch position relative to the gantry position. Similarly, position verification devices 125 can be coupled to various other components (e.g., the leaves 42 of the MLC 38, the gantry 18, the linear accelerator 26, etc) of the treatment system 10 in order to provide other position data. Additionally, in some embodiments, positioning devices and beacons can be coupled to, or implanted in patients 14 to provide patient 14 and target position information (as described in greater detail with respect to
In some embodiments, the LPS 100 can also be used to track the speed at which the components of the treatment system 10 are moving. More specifically, the speed of the components can be determined in a variety of methods by using the signals of the position verification devices 125. In one embodiment, the Doppler Effect is used to track the speed of each of moving components. In another embodiment, a position/time comparison calculation can be completed to determine the speed of each component of the treatment system 10. For example, the speed with which the linear accelerator 26 moves from one position to another around the gantry 18 can be tracked using the Doppler Effect by tracking a position verification device 125 fixed to the linear accelerator.
In order to track the position and speed of each of the verification devices 125, the signals that are received by the system monitoring module 110 are relayed to the integration computer 105. In some embodiments, the signals that are transmitted to the integration computer 105 from the system monitoring module 110 are relayed directly and without alteration. In other embodiments, the signals that are transmitted from the system monitoring module 110 to the integration computer 105 are modulated or altered prior to being sent. Alternatively, the system monitoring module 110 can be incorporated directly into the integration computer 105.
Upon receiving the signals from the system monitoring module 110, the integration computer 105 can complete the control loop that is created by the LPS 100, and transmit signals back to each of the plurality of system controllers (i.e., the gantry controller 20, the couch controller 70, the MLC controller 54, the dose controller 75, etc.). The signals that are transmitted from the integration computer 105 to each of the system controllers can then be used to alter the position and operation of the system components. Therefore, the integration computer 105 can effectively control the entire treatment system 10.
In one embodiment, the integration computer 105 of the LPS 100 can be used to compare the signals (e.g., motion signals such as position signals, velocity signals, acceleration signals, etc.) of each of the treatment system components to the signals of the position verification devices 125. For example, the position signal of a position verification device 125 that is coupled to the couch 62 can be cross-checked with a hard-wired position signal that is transmitted directly from the couch 62. If the position verification device signal differs from the signal produced by the couch 62, the integration computer 105 can determine if an alteration to the couch position needs to be made. The integration computer 105 can then transmit a correction signal to the couch controller 70 in order to move the couch 62 to the proper position.
In another embodiment, the speed of a component can be corrected with the LPS 100 using the integration computer 105. For example, the speed that is monitored with the position verification devices 125 can be compared to a speed signal that is produced from a hard-wired component of the linear accelerator 26. If the speed that is monitored with the position verification device 125 differs from that of a hard-wired connection, an alteration to the motion of the linear accelerator 26 can be made using the integration computer 105.
The LPS 100, therefore, can be used to gather a plurality of information from components of the treatment system 10 in order to temporally and spatially monitor and correct the motion of each component using absolute and relative reference points. In doing so, each of the components of the treatment system 10 that are being tracked by the position verification devices 125 can be coordinated and synchronized with each other to deliver the proper dose and treatment to the patient 14. For example, the couch 62, the linear accelerator 26, and the MLC 42 can all be synchronized, and have their motions verified in real-time by the integration computer 105 to deliver a treatment to the patient 14. Corrections to speed and position of the components of the treatment system 10 can be made as needed.
In another embodiment, the LPS 100 and/or other object positioning systems can interface and/or communicate with the treatment system 10 to conduct post-processing verification operations. It is noted that patient monitoring devices could also interface and/or communicate with the treatment system 10 to perform post-processing verification operations. After a treatment is completed, the signals of the position verification devices 125 can be reviewed. The hard-wired signals of each of the components of the treatment system 10 can also be reviewed. The signals from the position verification devices 125 can then be compared to the corresponding hard-wired signals. The results of the comparison can be used as a quality assurance check to verify that all of the components of the treatment system 10 have operated correctly. Faulty components and components that need to be replaced can potentially be identified using this comparison.
The position verification devices 125 (described above) of the LPS 100 are not limited to monitoring mechanical devices and components (i.e., the gantry 18, the MLC 38, the couch 62, etc.). Also, the verification aspects of this invention are not limited to the LPS devices described above. In another embodiment, a plurality of position monitoring devices can be coupled to, or implanted in the patient 14 in order to monitor, detect, and/or alter the dose 115 that is delivered during a treatment.
In some embodiments, reflector markers 205 are implanted near the target 46 of a patient 14, and used as a passive tracking and positioning beacon. The reflector markers 205 can also be positioned in a location that approximates the patient 14 (such as the couch 62). When the reflector marker 205 is excited by a trigger source, such as a radiation source, the position of the reflector marker 205 can be used to “localize” the position of the target 46. In some embodiments, the reflector markers are used in combination with CT imaging prior to, or during radiation treatment. The position data that is gained using the reflector markers 205 can confirm the patient 14 and target 46 locations with respect to the patient's anatomy. Therefore, the reflector markers can aid in directing the radiation therapy treatment toward the target 46. The reflector markers 205 can also be implanted in (or positioned near) other areas of the patient 14. For example, markers 205 can be implanted near an identified region at risk (“RAR”) in order to avoid exposing a particularly vulnerable area to radiation.
Transmitter markers 210 are another type of localizer, and can be used similarly to the reflector markers 205. However, the transmitter markers 210 do not require a trigger source to be activated. Therefore, depending on the configuration, the transmitter marker 210 can be located at any time during a treatment (and not only when the patient is being exposed to radiation). Transmitter markers 210 can transmit a variety of signals (e.g., RF, Bluetooth, WiFi, IEEE 802.15.4, and the like), which are received by a corresponding receiver.
In another embodiment, variable intensity seeds 215 can be used to track both the position of the patient 14 and the dose that is delivered to the patient 14. For example, an RF localization seed can be configured to produce a specific signal, which corresponds to a certain predetermined dose that is to be delivered to the patient 14. The configured RF seed can then be implanted into or near the target 46 of the patient 14. Each time the RF seed is exposed to a radiation treatment, the RF signal that is transmitted from the seed can become weaker. After the entire predetermined dose has been delivered, the seed will stop transmitting signal.
For radiation treatments that require multiple delivery sessions, the variable intensity seeds 215 can be probed for information prior to every treatment. In doing so, the amount of radiation that has been delivered to the patient prior to that delivery session can be verified. Additionally, the amount of radiation that has been received by the seed 215 can be verified with the amount of radiation that has been delivered by the treatment system 10. Those values can then be compared, and the operation of the treatment system 10 can be verified. In other embodiments, the seeds 215 can transmit their variable signal using a plurality of other techniques (including wireless and wired connections), such as WiFi, signals included in the IEEE 802.15 family, fiber optic connections, or traditional wire connections. Additionally, the seeds 215 can be varied in alternative ways in order to determine the dose that is delivered to the patient 14. For example, in some embodiments, the signal that is transmitted from the seeds 215 can increase, or get stronger, according to the amount of radiation that is received.
In some embodiments, the variable intensity seeds 215 can aid in determining deformation of the target 46 (e.g., how the target 46 reacts to the radiation treatment). For example, the markers, such as the variable intensity seeds 215, can be used as fiduciary points for deformation calculations. Deformation calculations can be made initially using a CT image, or by tracking the target 46 with one or more markers. An example deformation calculation is described in U.S. Provisional Patent Application No. 60/701,580; filed Jul. 22, 2005; titled SYSTEM AND METHOD FOR FEEDBACK GUIDED QUALITY ASSURANCE AND ADAPTATIONS TO RADIATION THERAPY TREATMENT, the entire content of which is incorporated herein by reference. The deformation of the target 46 can then be compared to the amount of radiation that is delivered to the patient 14, which can be calculated using the seeds 215. Radiation treatment strategies may be altered according to the amount of radiation that is received when compared to the amount of deformation that has occurred.
Once the position data has been collected, the predetermined dose can be delivered to the patient 14 (block 265). During delivery, the seeds 215 can be used to calculate the dose that is being received by the patient 14 (block 270). In some embodiments, the signal that is being transmitted from the seeds 215 is tracked continuously so that the amount of radiation that is being received by the patient can be tracked throughout a treatment. In other embodiments, the signal from the seeds 215 is read or polled at predetermined intervals. In order to verify that the correct dose is being received by the patient, the dose that is being delivered can be compared to the dose that is being received according to the seed 215 (block 275). If the amount of radiation that is being received by the patient 14 is relatively equal to the amount of radiation that is being delivered, a determination can be made whether or not to continue the treatment (block 280). The treatment can be ended (block 285) if the signal from the seed 215 is no longer present. However, if additional treatment is required, the process can return to block 255 in order to determine the proper dose to be delivered to the patient 14.
Referring again to block 275, if the amount of radiation that is being received by the patient 14 is not relatively equal to the amount of radiation that is being delivered by the treatment system 10, a determination whether or not to continue the treatment can be made (block 290). In some embodiments, a difference between the amount of radiation that is delivered to the patient 14 and the amount of radiation that is received by the patient 14 can signal a treatment system malfunction. Such a discrepancy may also be an indication that the improper area is being treated. In such embodiments, the treatment may be terminated (block 295). However, in some embodiments, adjustments can be made to alter the dose that is delivered, change position of the components of the treatment system 10, or change the position of the patient 14 (block 300). Such alterations can correct the delivery of the treatment so that the delivery can continue. After adjusting the necessary components, the process can return to block 255 so that the dose calculation can be completed for the subsequent delivery. An example dose calculation is also described in U.S. Provisional Patent Application No. 60/701,580.
In one embodiment, the process shown in
Referring back to
In one embodiment, a metal-oxide-semiconductor field effect transistor (“MOSFET”) marker 220, such as sensors or markers from Sicel Technologies, Inc. in Morrisville, N.C., can be used in combination with other localizer markers (such as markers 205 and 210) to aid in the optimized delivery of a dose to the patient 14. The localizer markers can be used to determine the location and deformation characteristics of the target 46, and the MOSFET marker 220 can be used to monitor the dose that is being received by the patient 14. The dose that is received by the patient 14, and tracked by the MOSFET marker 220, can then be compared to the dose that is actually delivered from the treatment system 10. The comparison of doses after a treatment can be used to detect systematic or random errors in treatment, and prepare for future remedial treatments or treatment modification. In other embodiments, the dose can be monitored by the MOSFET marker 220 throughout the treatment in real-time, and alterations can be made to the delivery strategy during the same treatment.
As shown in
The predicted dose calculation (block 360) can be compared to the dose that was monitored with the marker 220 (block 365) in order to verify that the dose that was received was equal or near to the dose that was delivered (block 370). After determining whether or not the treatment that was delivered to the patient 14 was equal to the treatment that was received by the patient 14 (block 370) the location of the target 46 can be considered (block 375). The conduciveness of a target 46 to be treated by radiation therapy can vary throughout the body. Therefore, in some cases, the amount of radiation that is delivered by the treatment system 10 can be greater than the dose that is received by the target 46. A report can be generated (block 380) that can indicate, based on prior knowledge of a target 46 and past treatments, the dose that should be received by the patient for a particular delivery. The deformation effects that are likely to occur can also be considered. Using the information of the certainty report and the dose data from the marker 220, the decision can be made whether or not a subsequent treatment is required (block 385). Using the markers 220 in this way can improve deformation calculations and validate projected deformation maps. The process ends if subsequent treatments are not needed (block 390). If another treatment is needed, the settings of the treatment system 10 can be adjusted (block 395) and the process can return to block 360. The position of the components of the treatment system 10 and the dose that is delivered may need to be adjusted based on the type of treatment, deformation, or patient position.
Referring back to
In one embodiment, the motion of the target 46 can be tracked using both the group 200 of markers and seeds, as well as with other devices (e.g., fluoroscopy, MVCT, kVCT, and the like). Then, during the delivery of a dose the treatment can be adapted or interrupted depending on the position of the target. For example, the lung of a patient 14 may need to be radiated. Due to the patient's need to breathe during treatment, the target 46 (i.e., the lung) may be in relatively constant motion. To track the motion of the lung, markers and seeds of the group 200 can be implanted in, or positioned proximate to the lung. The motion of the lung can also be monitored by other devices, such as those listed above. By tracking the motion of the lung the treatment that is being delivered can be adapted to include different doses according to the type of motion that is occurring. More specifically, the dose that is being delivered when the patient is breathing in may be different from the dose that is being delivered when the patient is breathing out. Additionally, the motion of the lung and the treatment that is delivered can be verified by comparing the signals of the markers and seeds of the group 200 to the signals of the other devices. If the results of the comparison are not consistent with each other, an error in treatment or an equipment malfunction can be identified. Erratic behavior of the lung (e.g., couching) can also be identified by the markers and seeds of the group 200 so that treatment can be paused or interrupted until the motion becomes more stable.
In another embodiment, the entire collection of devices that are used to track the components of the treatment system 10 and the group 200 of seeds and markers can be used to deliver a treatment to the patient 14. In one such embodiment, the motion of the components of the treatment system 10 and the target 46 are used to provide an optimized treatment using four dimensional, computed tomography (4D CT) images. 4D CT images can refer to a collection of 3D image volumes that each represents a “phase” of a motion pattern, such as breathing. These 4D CT images can be used for contouring, as well as for generating treatment plans that anticipate a certain cycle of phases. However, a patient's motion pattern can often deviate from the ideally reproducible pattern indicated by a 4D CT image set. The seeds and markers of the group 200 can be used to more accurately calculate dose for each of the volumes by monitoring the motion of the patient and/or system components during treatment. The motion that is tracked using the seeds and markers can be irregular or unexpected, and need not follow a smooth or reproducible trajectory. The position of each of the components of the treatment system 10 can also be verified during delivery. Using the measurements acquired by the various devices, an optimal dose can be recalculated for the patient's actual motion pattern. In another embodiment, the motion of the patient 14, the target 46, and the components of the treatment system 10 can be used to recalculate the dose for each phase of the 4D CT in real-time during a treatment. Deformation monitoring techniques (as described above) could also be used as a parameter to calculate and alter the dose between the different phases. Utilizing all of the data sources available can allow an optimized treatment.
Thus, the invention provides, among other things, new and useful systems and methods of determining position of an object and delivering radiation therapy treatment. Various features and advantages of the invention are set forth in the following claims.
This application claims the benefit of U.S. Provisional Patent Application No. 60/701,588; titled SYSTEM AND METHOD OF DETERMINING POSITION OF AN OBJECT AND DELIVERING RADIATION THERAPY TREATMENT; filed on Jul. 22, 2005; and the benefit of U.S. Provisional Patent Application No. 60/701,580; filed Jul. 22, 2005; titled SYSTEM AND METHOD FOR FEEDBACK GUIDED QUALITY ASSURANCE AND ADAPTATIONS TO RADIATION THERAPY TREATMENT; both of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3949265 | Holl | Apr 1976 | A |
3964467 | Rose | Jun 1976 | A |
4006422 | Schriber | Feb 1977 | A |
4032810 | Eastham et al. | Jun 1977 | A |
4149081 | Seppi | Apr 1979 | A |
4181894 | Pottier | Jan 1980 | A |
4189470 | Rose | Feb 1980 | A |
4208185 | Sawai et al. | Jun 1980 | A |
4273867 | Lin et al. | Jun 1981 | A |
4314180 | Salisbury | Feb 1982 | A |
4335465 | Christiansen et al. | Jun 1982 | A |
4388560 | Robinson et al. | Jun 1983 | A |
4393334 | Glaser | Jul 1983 | A |
4395631 | Salisbury | Jul 1983 | A |
4401765 | Craig et al. | Aug 1983 | A |
4426582 | Orloff et al. | Jan 1984 | A |
4446403 | Cuomo et al. | May 1984 | A |
4480042 | Craig et al. | Oct 1984 | A |
4570103 | Schoen | Feb 1986 | A |
4664869 | Mirzadeh et al. | May 1987 | A |
4703018 | Craig et al. | Oct 1987 | A |
4715056 | Vlasbloem et al. | Dec 1987 | A |
4736106 | Kashy et al. | Apr 1988 | A |
4752692 | Jergenson et al. | Jun 1988 | A |
4754760 | Fukukita et al. | Jul 1988 | A |
4815446 | McIntosh | Mar 1989 | A |
4818914 | Brodie | Apr 1989 | A |
4868844 | Nunan | Sep 1989 | A |
4870287 | Cole et al. | Sep 1989 | A |
4879518 | Broadhurst | Nov 1989 | A |
4912731 | Nardi | Mar 1990 | A |
4936308 | Fukukita et al. | Jun 1990 | A |
4987309 | Klasen et al. | Jan 1991 | A |
4998268 | Winter | Mar 1991 | A |
5003998 | Collett | Apr 1991 | A |
5008907 | Norman et al. | Apr 1991 | A |
5012111 | Ueda | Apr 1991 | A |
5065315 | Garcia | Nov 1991 | A |
5073913 | Martin | Dec 1991 | A |
5084682 | Swenson et al. | Jan 1992 | A |
5107222 | Tsuzuki | Apr 1992 | A |
5124658 | Adler | Jun 1992 | A |
5210414 | Wallace et al. | May 1993 | A |
5250388 | Schoch et al. | Oct 1993 | A |
5317616 | Swerdloff et al. | May 1994 | A |
5335255 | Seppi et al. | Aug 1994 | A |
5346548 | Mehta | Sep 1994 | A |
5351280 | Swerdloff et al. | Sep 1994 | A |
5382914 | Hamm et al. | Jan 1995 | A |
5391139 | Edmundson | Feb 1995 | A |
5394452 | Swerdloff et al. | Feb 1995 | A |
5405309 | Carden | Apr 1995 | A |
5442675 | Swerdloff et al. | Aug 1995 | A |
5453310 | Andersen et al. | Sep 1995 | A |
5466587 | Fitzpatrick-McElligott et al. | Nov 1995 | A |
5471516 | Nunan | Nov 1995 | A |
5483122 | Derbenev et al. | Jan 1996 | A |
5489780 | Diamondis | Feb 1996 | A |
5523578 | Herskovic | Jun 1996 | A |
5528650 | Swerdloff et al. | Jun 1996 | A |
5548627 | Swerdloff et al. | Aug 1996 | A |
5576602 | Hiramoto et al. | Nov 1996 | A |
5578909 | Billen | Nov 1996 | A |
5581156 | Roberts et al. | Dec 1996 | A |
5596619 | Carol | Jan 1997 | A |
5596653 | Kurokawa | Jan 1997 | A |
5621779 | Hughes et al. | Apr 1997 | A |
5622187 | Carol | Apr 1997 | A |
5625663 | Swerdloff et al. | Apr 1997 | A |
5627041 | Shartle | May 1997 | A |
5641584 | Andersen et al. | Jun 1997 | A |
5647663 | Holmes | Jul 1997 | A |
5651043 | Tsuyuki et al. | Jul 1997 | A |
5661377 | Mishin et al. | Aug 1997 | A |
5661773 | Swerdloff et al. | Aug 1997 | A |
5667803 | Paronen et al. | Sep 1997 | A |
5668371 | Deasy et al. | Sep 1997 | A |
5673300 | Reckwerdt et al. | Sep 1997 | A |
5692507 | Seppi et al. | Dec 1997 | A |
5695443 | Brent et al. | Dec 1997 | A |
5712482 | Gaiser et al. | Jan 1998 | A |
5721123 | Hayes et al. | Feb 1998 | A |
5724400 | Swerdloff et al. | Mar 1998 | A |
5729028 | Rose | Mar 1998 | A |
5734168 | Yao | Mar 1998 | A |
5747254 | Pontius | May 1998 | A |
5751781 | Brown et al. | May 1998 | A |
5753308 | Andersen et al. | May 1998 | A |
5754622 | Hughes | May 1998 | A |
5754623 | Seki | May 1998 | A |
5760395 | Johnstone | Jun 1998 | A |
5802136 | Carol | Sep 1998 | A |
5811944 | Sampayan et al. | Sep 1998 | A |
5818058 | Nakanishi et al. | Oct 1998 | A |
5818902 | Yu | Oct 1998 | A |
5820553 | Hughes | Oct 1998 | A |
5821051 | Androphy et al. | Oct 1998 | A |
5821705 | Caporaso et al. | Oct 1998 | A |
5834454 | Kitano et al. | Nov 1998 | A |
5836905 | Lemelson et al. | Nov 1998 | A |
5842175 | Andros et al. | Nov 1998 | A |
5866912 | Slater et al. | Feb 1999 | A |
5870447 | Powell et al. | Feb 1999 | A |
5877023 | Sautter et al. | Mar 1999 | A |
5877192 | Lindberg et al. | Mar 1999 | A |
5912134 | Shartle | Jun 1999 | A |
5920601 | Nigg et al. | Jul 1999 | A |
5953461 | Yamada | Sep 1999 | A |
5962995 | Avnery | Oct 1999 | A |
5963615 | Egley et al. | Oct 1999 | A |
5969367 | Hiramoto et al. | Oct 1999 | A |
5977100 | Kitano et al. | Nov 1999 | A |
5983424 | Naslund | Nov 1999 | A |
5986274 | Akiyama et al. | Nov 1999 | A |
6011825 | Welch et al. | Jan 2000 | A |
6020135 | Levine et al. | Feb 2000 | A |
6020538 | Han et al. | Feb 2000 | A |
6029079 | Cox et al. | Feb 2000 | A |
6038283 | Carol et al. | Mar 2000 | A |
6049587 | Leksell et al. | Apr 2000 | A |
6066927 | Koudijs | May 2000 | A |
6069459 | Koudijs | May 2000 | A |
6071748 | Modlin et al. | Jun 2000 | A |
6094760 | Nonaka et al. | Aug 2000 | A |
6127688 | Wu | Oct 2000 | A |
6152599 | Salter | Nov 2000 | A |
6171798 | Levine et al. | Jan 2001 | B1 |
6178345 | Vilsmeier et al. | Jan 2001 | B1 |
6197328 | Yanagawa | Mar 2001 | B1 |
6198957 | Green | Mar 2001 | B1 |
6200959 | Haynes et al. | Mar 2001 | B1 |
6204510 | Ohkawa | Mar 2001 | B1 |
6207400 | Kwon | Mar 2001 | B1 |
6218675 | Akiyama et al. | Apr 2001 | B1 |
6222905 | Yoda et al. | Apr 2001 | B1 |
6241670 | Nambu | Jun 2001 | B1 |
6242747 | Sugitani et al. | Jun 2001 | B1 |
6264825 | Blackburn et al. | Jul 2001 | B1 |
6265837 | Akiyama et al. | Jul 2001 | B1 |
6279579 | Riaziat et al. | Aug 2001 | B1 |
6291823 | Doyle et al. | Sep 2001 | B1 |
6316776 | Hiramoto et al. | Nov 2001 | B1 |
6319469 | Mian et al. | Nov 2001 | B1 |
6322249 | Wofford et al. | Nov 2001 | B1 |
6331194 | Elizondo-Decanini et al. | Dec 2001 | B1 |
6345114 | Mackie et al. | Feb 2002 | B1 |
6360116 | Jackson, Jr. et al. | Mar 2002 | B1 |
6385286 | Fitchard et al. | May 2002 | B1 |
6385288 | Kanematsu | May 2002 | B1 |
6393096 | Carol et al. | May 2002 | B1 |
6405072 | Cosman | Jun 2002 | B1 |
6407505 | Bertsche | Jun 2002 | B1 |
6417178 | Klunk et al. | Jul 2002 | B1 |
6424856 | Vilsmeier et al. | Jul 2002 | B1 |
6428547 | Vilsmeier et al. | Aug 2002 | B1 |
6433349 | Akiyama et al. | Aug 2002 | B2 |
6438202 | Olivera et al. | Aug 2002 | B1 |
6455844 | Meyer | Sep 2002 | B1 |
6462490 | Matsuda et al. | Oct 2002 | B1 |
6465957 | Whitham et al. | Oct 2002 | B1 |
6466644 | Hughes et al. | Oct 2002 | B1 |
6469058 | Grove et al. | Oct 2002 | B1 |
6472834 | Hiramoto et al. | Oct 2002 | B2 |
6473490 | Siochi | Oct 2002 | B1 |
6475994 | Tomalia et al. | Nov 2002 | B2 |
6482604 | Kwon | Nov 2002 | B2 |
6484144 | Martin et al. | Nov 2002 | B2 |
6487274 | Bertsche | Nov 2002 | B2 |
6493424 | Whitham | Dec 2002 | B2 |
6497358 | Walsh | Dec 2002 | B1 |
6498011 | Hohn et al. | Dec 2002 | B2 |
6500343 | Siddiqi | Dec 2002 | B2 |
6504899 | Pugachev et al. | Jan 2003 | B2 |
6510199 | Hughes et al. | Jan 2003 | B1 |
6512942 | Burdette et al. | Jan 2003 | B1 |
6516046 | Frohlich et al. | Feb 2003 | B1 |
6527443 | Vilsmeier et al. | Mar 2003 | B1 |
6531449 | Khojasteh et al. | Mar 2003 | B2 |
6535837 | Schach Von Wittenau | Mar 2003 | B1 |
6552338 | Doyle | Apr 2003 | B1 |
6558961 | Sarphie et al. | May 2003 | B1 |
6560311 | Shepard et al. | May 2003 | B1 |
6562376 | Hooper et al. | May 2003 | B2 |
6584174 | Schubert et al. | Jun 2003 | B2 |
6586409 | Wheeler | Jul 2003 | B1 |
6605297 | Nadachi et al. | Aug 2003 | B2 |
6611700 | Vilsmeier et al. | Aug 2003 | B1 |
6617768 | Hansen | Sep 2003 | B1 |
6618467 | Ruchala et al. | Sep 2003 | B1 |
6621889 | Mostafavi | Sep 2003 | B1 |
6633686 | Bakircioglu et al. | Oct 2003 | B1 |
6634790 | Salter, Jr. | Oct 2003 | B1 |
6636622 | Mackie et al. | Oct 2003 | B2 |
6637056 | Tybinkowski et al. | Oct 2003 | B1 |
6646383 | Bertsche et al. | Nov 2003 | B2 |
6653547 | Akamatsu | Nov 2003 | B2 |
6661870 | Kapatoes et al. | Dec 2003 | B2 |
6688187 | Masquelier | Feb 2004 | B1 |
6690965 | Riaziat et al. | Feb 2004 | B1 |
6697452 | Feb 2004 | B2 | |
6705984 | Angha | Mar 2004 | B1 |
6713668 | Akamatsu | Mar 2004 | B2 |
6713976 | Zumoto et al. | Mar 2004 | B1 |
6714620 | Caflisch et al. | Mar 2004 | B2 |
6714629 | Vilsmeier | Mar 2004 | B2 |
6716162 | Hakamata | Apr 2004 | B2 |
6723334 | McGee et al. | Apr 2004 | B1 |
6760402 | Ghelmansarai | Jul 2004 | B2 |
6774383 | Norimine et al. | Aug 2004 | B2 |
6787771 | Garty et al. | Sep 2004 | B2 |
6787983 | Yamanobe et al. | Sep 2004 | B2 |
6788764 | Saladin et al. | Sep 2004 | B2 |
6792073 | Deasy et al. | Sep 2004 | B2 |
6796164 | McLoughlin et al. | Sep 2004 | B2 |
6800866 | Amemiya et al. | Oct 2004 | B2 |
6822244 | Beloussov et al. | Nov 2004 | B2 |
6822247 | Sasaki | Nov 2004 | B2 |
6838676 | Jackson | Jan 2005 | B1 |
6842502 | Jaffray et al. | Jan 2005 | B2 |
6844689 | Brown et al. | Jan 2005 | B1 |
6871171 | Agur et al. | Mar 2005 | B1 |
6873115 | Sagawa et al. | Mar 2005 | B2 |
6873123 | Marchand et al. | Mar 2005 | B2 |
6878951 | Ma | Apr 2005 | B2 |
6882702 | Luo | Apr 2005 | B2 |
6882705 | Egley et al. | Apr 2005 | B2 |
6888326 | Amaldi et al. | May 2005 | B2 |
6889695 | Pankratov et al. | May 2005 | B2 |
6922455 | Jurczyk et al. | Jul 2005 | B2 |
6929398 | Tybinkowski et al. | Aug 2005 | B1 |
6936832 | Norimine et al. | Aug 2005 | B2 |
6955464 | Tybinkowski et al. | Oct 2005 | B1 |
6963171 | Sagawa et al. | Nov 2005 | B2 |
6974254 | Paliwal et al. | Dec 2005 | B2 |
6984835 | Harada | Jan 2006 | B2 |
6990167 | Chen | Jan 2006 | B2 |
7015490 | Wang et al. | Mar 2006 | B2 |
7046762 | Lee | May 2006 | B2 |
7051605 | Lagraff et al. | May 2006 | B2 |
7060997 | Norimine et al. | Jun 2006 | B2 |
7077569 | Tybinkowski et al. | Jul 2006 | B1 |
7081619 | Bashkirov et al. | Jul 2006 | B2 |
7084410 | Beloussov et al. | Aug 2006 | B2 |
7087200 | Taboas et al. | Aug 2006 | B2 |
7112924 | Hanna | Sep 2006 | B2 |
7130372 | Kusch et al. | Oct 2006 | B2 |
7154991 | Earnst et al. | Dec 2006 | B2 |
7186986 | Hinderer et al. | Mar 2007 | B2 |
7186991 | Kato et al. | Mar 2007 | B2 |
7203272 | Chen | Apr 2007 | B2 |
7209547 | Baier et al. | Apr 2007 | B2 |
7221733 | Takai et al. | May 2007 | B1 |
7252307 | Kanbe et al. | Aug 2007 | B2 |
7257196 | Brown et al. | Aug 2007 | B2 |
20020007918 | Owen et al. | Jan 2002 | A1 |
20020077545 | Takahashi et al. | Jun 2002 | A1 |
20020080915 | Frohlich | Jun 2002 | A1 |
20020085668 | Blumhofer et al. | Jul 2002 | A1 |
20020091314 | Schlossbauer et al. | Jul 2002 | A1 |
20020115923 | Erbel | Aug 2002 | A1 |
20020120986 | Erbel et al. | Sep 2002 | A1 |
20020122530 | Erbel et al. | Sep 2002 | A1 |
20020136439 | Ruchala et al. | Sep 2002 | A1 |
20020150207 | Kapatoes et al. | Oct 2002 | A1 |
20020187502 | Waterman et al. | Dec 2002 | A1 |
20020193685 | Mate et al. | Dec 2002 | A1 |
20030007601 | Jaffray et al. | Jan 2003 | A1 |
20030031298 | Feb 2003 | A1 | |
20030086527 | Speiser et al. | May 2003 | A1 |
20030105650 | Lombardo et al. | Jun 2003 | A1 |
20030174872 | Chalana et al. | Sep 2003 | A1 |
20040010418 | Buonocore et al. | Jan 2004 | A1 |
20040068182 | Misra | Apr 2004 | A1 |
20040116804 | Mostafavi | Jun 2004 | A1 |
20040165696 | Lee | Aug 2004 | A1 |
20040202280 | Besson | Oct 2004 | A1 |
20040230115 | Scarantino et al. | Nov 2004 | A1 |
20040254492 | Zhang et al. | Dec 2004 | A1 |
20040254773 | Zhang et al. | Dec 2004 | A1 |
20040264640 | Myles | Dec 2004 | A1 |
20050013406 | Dyk et al. | Jan 2005 | A1 |
20050031181 | Bi et al. | Feb 2005 | A1 |
20050080332 | Shiu et al. | Apr 2005 | A1 |
20050096515 | Geng | May 2005 | A1 |
20050123092 | Mistretta et al. | Jun 2005 | A1 |
20050143965 | Failla et al. | Jun 2005 | A1 |
20050180544 | Sauer et al. | Aug 2005 | A1 |
20050197564 | Dempsey | Sep 2005 | A1 |
20050251029 | Khamene et al. | Nov 2005 | A1 |
20060074292 | Thomson et al. | Apr 2006 | A1 |
20060083349 | Harari et al. | Apr 2006 | A1 |
20060100738 | Alsafadi et al. | May 2006 | A1 |
20060133568 | Moore | Jun 2006 | A1 |
20060193429 | Chen | Aug 2006 | A1 |
20060193441 | Cadman | Aug 2006 | A1 |
20060285639 | Olivera et al. | Dec 2006 | A1 |
20070041494 | Ruchala et al. | Feb 2007 | A1 |
20070041495 | Olivera et al. | Feb 2007 | A1 |
20070041497 | Schnarr et al. | Feb 2007 | A1 |
20070041498 | Olivera et al. | Feb 2007 | A1 |
20070041499 | Lu et al. | Feb 2007 | A1 |
20070041500 | Olivera et al. | Feb 2007 | A1 |
20070043286 | Lu et al. | Feb 2007 | A1 |
20070076846 | Ruchala et al. | Apr 2007 | A1 |
20070088573 | Ruchala et al. | Apr 2007 | A1 |
20070104316 | Ruchala et al. | May 2007 | A1 |
20070127623 | Goldman et al. | Jun 2007 | A1 |
20070189591 | Lu et al. | Aug 2007 | A1 |
20070195922 | Mackie et al. | Aug 2007 | A1 |
20070195930 | Kapatoes et al. | Aug 2007 | A1 |
20070201613 | Lu et al. | Aug 2007 | A1 |
Number | Date | Country |
---|---|---|
2091275 | Sep 1993 | CA |
2180227 | Dec 1996 | CA |
261523 | Sep 2006 | TW |
2004057515 | Jul 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20070195929 A1 | Aug 2007 | US |
Number | Date | Country | |
---|---|---|---|
60701588 | Jul 2005 | US | |
60701580 | Jul 2005 | US |